These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 12642122

  • 1. The role of hydroxyurea in the management of sickle cell disease.
    Davies SC, Gilmore A.
    Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
    [Abstract] [Full Text] [Related]

  • 2. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI, Onodingene NM, Okoye HC, Omunakwe HE.
    Ann Afr Med; 2021 Jun; 20(2):127-131. PubMed ID: 34213480
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 5. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
    Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L.
    J Pediatr Hematol Oncol; 2000 Feb 28; 22(4):330-4. PubMed ID: 10959903
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO, Bolarinwa AB, Adekile AD.
    Hemoglobin; 2019 May 28; 43(3):188-192. PubMed ID: 31462098
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM, Wakamb GK, Mulangu AM, Nkashama GM, Kupa BK, Numbi OL.
    Pan Afr Med J; 2015 May 28; 21():124. PubMed ID: 26327961
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW, Al-Hajri M, Beshlawi I, Al-Shahrabally A, Elshinawy M, Zachariah M, Mevada ST, Bashir W, Rawas A, Taqi A, Al-Lamki Z, Wali Y.
    Eur J Haematol; 2013 Jun 28; 90(6):519-24. PubMed ID: 23489171
    [Abstract] [Full Text] [Related]

  • 15. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P, Pecoraro A, Calvaruso G, Steinberg MH, Iannello S, Maggio A.
    Am J Hematol; 2013 Nov 28; 88(11):E261-4. PubMed ID: 23828131
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
    Saleh AW, Velvis HJ, Gu LH, Hillen HF, Huisman TH.
    Acta Haematol; 1997 Nov 28; 98(3):125-9. PubMed ID: 9352741
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A, Scoble J, Snowden S, Hambley H, Bellingham A.
    Nephron; 1997 Nov 28; 75(1):106-7. PubMed ID: 9031282
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.